Trepmac90mg
Rx- Generic:
- Brigatinib
- Company:
- Genvio Pharma Ltd.
- Dosage form:
- Tablet
- Pack size:
- Box (30 Tablet)
৳ 1,400/unit
Pack: ৳ 42,000
Price comparison
- This brand
- ৳ 1400
- Cheapest of this genericBigatab
- ৳ 350
The cheaper brand costs ৳ 1050.00 less per unit
Compared against 3 brands
At a glance
Brigatinib is a tyrosine kinase inhibitor used in the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib.
Indications
- Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) - in patients who have progressed on or are intolerant to crizotinib
Dosage
Adults (ALK-positive metastatic NSCLC):
First 7 days: 90 mg PO qDay (with or without food).
If 90 mg/day is tolerated: Increase dose to 180 mg PO qDay.
Continue until disease progression or unacceptable toxicity.
Hepatic impairment:
Mild or moderate (Child-Pugh A or B): No dose adjustment required.
Severe (Child-Pugh C): Reduce once daily dose by ~40% (e.g., 180 mg to 120 mg, 120 mg to 90 mg, or 90 mg to 60 mg).
Renal impairment:
Mild or moderate (CrCl 30-89 mL/min): No dose adjustment required.
Severe (CrCl 15-29 mL/min): Reduce dose by ~50% (e.g., 180 mg to 90 mg, or 90 mg to 60 mg).
Side effects
>10%: Increased AST (38%), Hyperglycemia (38%), Increased ALT (34%), Nausea (33%), Fatigue (29%), Headache (28%), Increased CPK (27%), Increased amylase (27%), Dyspnea (27%), Vomiting (24%), Anemia (23%), Decreased appetite (22%), Prolonged aPTT (22%), Increased lipase (21%), Diarrhea (19%), Constipation (19%), Lymphopenia (19%), Cough (18%), Abdominal pain (17%), Increased alkaline phosphatase (15%), Decreased phosphorous (15%), Rash (15%), Pyrexia (14%), Arthralgia (14%), Peripheral neuropathy (13%), Muscle spasms (12%), Hypertension (11%), Pain in extremity (11%), Insomnia (11%).
1-10%: Back pain (10%), Myalgia (9.2%), Visual disturbances (7.3%), Pneumonia (4.6%), Interstitial lung disease/pneumonitis (3.7%).
<1%: Hypoxia (0.9%).
Precautions & warnings
- Interstitial lung disease (ILD)/pneumonitis: Risk exists; discontinue for Grade 3 or 4 ILD/pneumonitis or recurrence of Grade 1/2 ILD.
- Hypertension (HTN): Discontinue for Grade 4 HTN or recurrence of Grade 3 HTN.
- Bradycardia: Discontinue for life-threatening bradycardia; caution with antihypertensives causing bradycardia.
- Visual disturbances: Blurred vision, diplopia, reduced visual acuity; discontinue for Grade 4.
- CPK and pancreatic enzyme elevation: Withhold treatment for Grade 3 or 4 elevation.
- Hyperglycemia: Withhold treatment for inadequate glycemic control.
- Contraception: Females of reproductive potential should use effective non-hormonal contraception during treatment and for at least 4 months after the final dose; males should use effective contraception during treatment and for at least 3 months after the last dose.
- Do not use during pregnancy and lactation; not for use in children.